Glenmark Pharmaceuticals today said it has received the final approval from US health regulator for its generic version of Desmopressin Acetate tablets used in the treatment of diabetes and bed-wetting.
The approval by the US Food and Drug Administration (USFDA) is for strengths of 0.1 mg and 0.2 mg and the company plans to immediately begin shipments to the US, Glenmark said in a statement.
Desmopressin Acetate is sold under the trademark DDAVP by Ferring Pharmaceuticals. Citing IMS data, Glenmark said: “DDAVP market achieved annual sales of approximately $72.1 million in the 12 month period ended March 2015.’’
Glenmark’s current portfolio consists of 97 products authorised for distribution in the US and 68 abbreviated new drug approvals with the USFDA.
Shares of Glenmark Pharmaceuticals were trading at Rs. 872 per scrip in afternoon trade, up 1.71 per cent from the previous close on the BSE. PTI
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…